Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for AMEX:INO
+0.07 (0.79%)
Real-time:   2:08PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.75 - 8.95
52 week 7.48 - 15.80
Open 8.77
Vol / Avg. 216,866.00/640,632.00
Mkt cap 546.62M
P/E     -
Div/yield     -
EPS -0.79
Shares 60.59M
Beta 2.97
Inst. own 23%
Mar 16, 2015
Q4 2014 Inovio Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 9, 2015
Inovio Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference - 9:30AM EST - Add to calendar
Jan 12, 2015
Inovio Pharmaceuticals Inc at EBD Biotech Showcase
Nov 24, 2014
Inovio Pharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference
Nov 13, 2014
Inovio Pharmaceuticals Inc at Drexel Hamilton Micro-Cap Investor Forum
Nov 10, 2014
Q3 2014 Inovio Pharmaceuticals Inc Earnings Release
Nov 10, 2014
Q3 2014 Inovio Pharmaceuticals Inc Earnings Call
Nov 4, 2014
Inovio Pharmaceuticals Inc at EBD Group BIO-Europe Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -390.09% -490.69%
Operating margin -452.69% -145.12%
EBITD margin - -139.17%
Return on average assets -20.81% -99.06%
Return on average equity -24.13% -152.12%
Employees 71 -
CDP Score - -


United States - Map
+1-858-5976006 (Phone)
+1-267-4404242 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Inovio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. As of December 31, 2011 it owned 16.1% interest in VGX Int�l.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Jennifer Laux Vice President - Commercial
Bio & Compensation  - Reuters
Zane Yang Vice President - Clinical Development, Oncology
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 69
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Mort Collins Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters